The key to regulating checkpoint pathways may all boil down to one very conserved and inescapable signaling molecular relationship which I believe NWBO understands very well. This is the reason their checkpoint combination patent will stand up over time and is a thorn in the side of big pharma and their investor advocates alike. Best wishes.
News 
Market Data 
Discover 
